Industry context
Alnylam Pharmaceuticals [ALNY]
最終更新 25 Jun 2026 @ 16:00 (Exchange is closed)
直近: $293.17
-0.30%
-0.61 (↑)
GaG Algo Score™
v1.0
短期
-0.61 (↑)
中期
-2.21 (↑)
長期
-2.22 (↑)
買い
64.00%
リターン 13.69%
売り
79.59%
リターン 26.77%
ライン
ピボットデータ
ピボット統計
| 指標 | 平均 | 中央値 | 標準偏差 |
|---|---|---|---|
| 上昇 % | 6.61% | 6.61% | 0.69% |
| 下落 % | -7.31% | -7.31% | 1.56% |
| 期間 | 9.5d | 10d | 7.1d |
| 検出ピボット合計 | 5 |
| 上昇/下落区間 | 4 (2 上昇 / 2 下落) |
| 直近ピボット | Bottom @ $278.09 日付 2026-06-18 |
| 直近ピボットからの変化 | $15.08 (5.42%) |
次のピボット予測 直近: $293.17
| 予測される次のタイプ | Top |
| 予測価格（平均） | $296.47 |
| 予測価格（中央値） | $296.47 |
| 予測価格レンジ (~68%) | $294.56 - $298.39 |
| 平均目標までの変化 | $3.30 (1.13%) |
| 予測日（平均） | 2026-06-27 |
| 予測日レンジ (~68%) | 2026-06-20 - 2026-07-04 |
| 根拠 | Based on 2 historical gains (Avg: 6.61%, Median: 6.61%, StdDev: 0.69%) and duration (Avg: 9.5 days, StdDev: 7.1 days) |
| 注記 | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Slight loss for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (ALNY) stock price slightly decreased on Thursday after the stock fell $-0.890 (-0.30%) from the previous session on normal volume. The stock moved in line with the falling NASDAQ that fell -0.46%. Yesterday's trading volume was 1.13M shares, worth about $329.92M. This represents 174 296 shares less than the day before. Volume was close to the 10-day average of 1.31M shares.
Alnylam Pharmaceuticals signals
There is no conclusive signals given from RSI. The price is above the short-term average yet below the long-term average, with the short-term average still below the long-term average; signals are mixed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-16.7%), medium- (-16.7%), and long-term (-16.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Alnylam Pharmaceuticals Support & Resistance Levels
The stock is trading above the closest support level at $293.00. approximately $0.170 (0.06%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s1293 -
Alnylam Pharmaceuticals Evaluation
- 短期 スコア: -0.61
- 中期 スコア: -2.21
- 長期 スコア: -2.22
Ownership flow
GetAGraph InsiderPower
Transactions
1 193
Buy power
322.67M
Sell power
226.58M
Reliability
100/100
Buy / sell
1.42
Hist. corr.
-0.65
Latest signal
Buy 2026-05-29
Officer 1025
Director 168
2026-06-01
Pyott David E I Director
Buy 3 830
2026-06-01
Pyott David E I Director
Sell 921
2026-06-01
Pyott David E I Director
Sell 1 175
2026-06-01
Pyott David E I Director
Sell 1 222
2026-06-01
Pyott David E I Director
Sell 495
2026-06-01
Pyott David E I Director
Sell 17
Relationship map
Correlation snapshot
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.36% <strong>$293.79</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
4.01%
Of outstanding shares
Short float
4.08%
Of tradable float
Days to cover
5.78
Short interest divided by average volume
Squeeze probability
5.10%
-1.83% change
Short interest is worth monitoring, but the setup is not extreme.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
9
EPS misses
1
Avg. surprise
70.78%
Alnylam Pharmaceuticals Inc Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Miss
Q2/2023
Beat
Q3/2023
Beat
Q4/2023
Beat
Q1/2024
Beat
Q2/2024
Beat
Q3/2024
Beat
Q4/2024
Beat
Q1/2025
Waiting
Q2/2025
Waiting
Q3/2025
Alnylam Pharmaceuticals Inc Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-10-29 | Q3/2025 | - | - | Waiting | - | - | Waiting |
| 2025-08-07 | Q2/2025 | $-0.420 | - | Waiting | - | - | Waiting |
| 2025-05-01 | Q1/2025 | $-0.890 | $-0.0100 | Beat 98.88% | 585.14M | 594.19M | Beat 1.55% |
| 2025-02-13 | Q4/2024 | $-0.620 | $0.0600 | Beat 109.68% | 582.61M | 593.17M | Beat 1.81% |
| 2024-10-31 | Q3/2024 | $-0.917 | $-0.500 | Beat 45.45% | 532.91M | 500.92M | Miss -6.00% |
| 2024-08-01 | Q2/2024 | $-1.070 | $0.560 | Beat 152.34% | 447.22M | 659.83M | Beat 47.54% |
| 2024-05-02 | Q1/2024 | $-1.120 | $-0.160 | Beat 85.71% | 428.01M | 494.33M | Beat 15.50% |
| 2024-02-15 | Q4/2023 | $-1.200 | $-1.100 | Beat 8.33% | 442.90M | 439.72M | Miss -0.72% |
| 2023-11-02 | Q3/2023 | $-1.340 | $1.150 | Beat 185.82% | 401.03M | 750.53M | Beat 87.15% |
| 2023-08-03 | Q2/2023 | $-1.720 | $-2.21 | Miss -28.49% | 350.51M | 318.75M | Miss -9.06% |
| 2023-05-04 | Q1/2023 | $-1.970 | $-1.400 | Beat 28.93% | 312.26M | 319.29M | Beat 2.25% |
| 2023-02-23 | Q4/2022 | $-2.13 | $-1.680 | Beat 21.13% | 313.13M | 335.04M | Beat 6.99% |
Analyst view
Analyst targets
Consensus
$454.27
Median
$447.00
Low
$370.00
High
$530.00
News flow
Latest company news
Market coverage
seekingalpha.com Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript Jun 25, 2026 businesswire.com Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform Jun 25, 2026 zacks.com Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? Jun 22, 2026 forbes.com The Healthcare M&A Wave Jun 17, 2026Company releases
Company context
Company profile
取引所:
NASDAQ
セクター:
Healthcare
業種:
Biotechnology
Currency
USD
Alnylam Pharmaceuticals Inc is a biopharmaceutical company primarily dedicated to the discovery development and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference RNAi technology Its robust pipeline of RNAibased treatments addresses a range of critical therapeutic areas including inherited genetic disorders cardiometabolic conditions hepatic infectious diseases and central nervous system CNS and ocular disorders Currently Alnylam offers several approved therapies ONPATTRO patisiran for adults suffering from polyneuropathy associated with hereditary transthyretinmediated amyloidosis GIVLAARI for adult patients with acute hepatic porphyria AHP and OXLUMO lumasiran for primary hyperoxaluria type 1 PH1 Beyond its commercial portfolio the company maintains an active development pipeline Key investigational therapies include givosiran aimed at adolescent patients with AHP patisiran being explored for transthyretin amyloidosis ATTR with cardiomyopathy cemdisiran for complementmediated disorders ALNAAT02 for AAT deficiencyassociated liver disease ALNHBV02 for chronic hepatitis B virus infection Zilebesiran for hypertension and ALNHSD for nonalcoholic steatohepatitis NASH Additionally other candidates such as Fitusiran for hemophilia and bleeding disorders Inclisiran for hypercholesterolemia an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones and vutrisiran for ATTR amyloidosis currently in Phase 3 clinical trials are also progressing Alnylam also engages in strategic alliances with other pharmaceutical leaders Notable collaborations include those with Regeneron Pharmaceuticals Inc focused on discovering and developing RNAi therapeutics for ocular and CNS targets and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts Further licensing and partnership agreements are in place with entities such as Novartis AG Vir Biotechnology Inc Dicerna Pharmaceuticals Inc Ionis Pharmaceuticals Inc and PeptiDream Inc Established in 2002 Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge Massachusetts
Navigation